Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–27 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: RAS Family Gene Mutation Clear all

Completed Phase 2 Interventional

Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer

NCT00300950

View directory record Official record

Conditions: Pancreas Cancer
Interventions: GI-4000, Gemcitabine; Biological · Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older

Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 18
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 14 more

Source: ClinicalTrials.gov public record

Updated Apr 5, 2015 · Synced May 21, 2026, 6:32 PM EDT

Recruiting Phase 1Phase 2 Interventional

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

NCT07397338

View directory record Official record

Conditions: Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC
Interventions: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only), cetuximab (Cohort C2 Only), Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only), Daraxonrasib (Cohort B1 only); Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Norwich, Connecticut • Nashville, Tennessee • Irving, Texas + 2 more

Source: ClinicalTrials.gov public record

Updated May 11, 2026 · Synced May 21, 2026, 6:32 PM EDT

Recruiting Phase 3 Interventional

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07491445

View directory record Official record

Conditions: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Interventions: daraxonrasib, gemcitabine, nab-paclitaxel; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Henderson, Nevada • Maumee, Ohio

Source: ClinicalTrials.gov public record

Updated May 13, 2026 · Synced May 21, 2026, 6:32 PM EDT